GH Research PLC (GHRS) NASDAQ
24.87
+0.04(+0.16%)
Currency In USD
- General
- Statistics
- Historical Data
- Profile
- Financials
24.87
+0.04(+0.16%)
Currency In USD
Sector
Healthcare
Industry
Biotechnology
Employees
50
First IPO Date
June 25, 2021
| Name | Title | Pay | Year Born |
| Velichka Valcheva | Chief Executive Officer | 0 | 1975 |
| Aaron Cameron | Chief Operating Officer | 0 | 1985 |
| Florian Schonharting | Co-Founder & Non-Executive Chairman of the Board | 0 | 1969 |
| Magnus Halle | Co-Founder & MD of Ireland | 0 | 1997 |
| Julie Ryan | Vice President of Finance | 0 | 1986 |
GH Research PLC, a clinical-stage biopharmaceutical company, engages in developing various therapies for the treatment of psychiatric and neurological disorders. The company focuses on developing 5-Methoxy-N,N-Dimethyltryptamine (5-MeO-DMT) therapies for the treatment of patients with treatment-resistant depression (TRD). Its lead program is GH001, an inhalable 5-MeO-DMT product candidate that has completed two Phase 1 clinical trials and Phase 1/2 clinical trial in patients with TRD. The company also develops GH002, an injectable 5-MeO-DMT product candidate; and GH003, an intranasal 5-MeO-DMT product candidate, which are in preclinical development trials with a focus on psychiatric and neurological disorders. GH Research PLC was incorporated in 2018 and is based in Dublin, Ireland.